Safety and Clinical Outcomes of an Equine-Derived Heptavalent Botulinum Antitoxin Treatment for Confirmed or Suspected Botulism in the United States

 Treatment with BAT® [Botulism Antitoxin Heptavalent (Equine)] was associated with shorter hospital and intensive care unit stays.

Emergent BioSolutions awarded contract from HHS to support smallpox preparedness

The US Department of Health and Human Services (HHS) awarded a contract for $535 to Emergent BioSolutions Inc. for Vaccinia Immune Globulin Intravenous (VIGIV) to be used in the Strategic National Stockpile. VIGIV is the only therapeutic licensed by the US Food and Drug Administration (FDA) for the treatment of complications due to smallpox vaccination.

Assessing a drug for an eradicated human disease: US Food and Drug Administration review of tecovirimat for the treatment of smallpox

The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule.

A pill that mimics natural antibodies could fight many kinds of flu

A pharmaceutical company has developed a conventional drug that mimics the effect of antibodies that are effective against a wide range of flu viruses. Conventional drugs are cheaper and easier to make and store than antibodies and can be taken in pill form. The hope is that this antibody-mimicking strategy could lead to new treatments for many viral diseases.

Improving the Care and Treatment of Monkeypox Patients in Low-Resource Settings: Applying Evidence from Contemporary Biomedical and Smallpox Biodefense Research

This paper summarizes clinical syndromes and possible treatment options, for both developed and low-resource settings, and offer performance indicators and clinical metrics for case management.